SCHEMBL288343

SCHEMBL288343

CCCCCCCCNCC(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.56
PPARG P37231 7/20 0.56
PPARD Q03181 7/20 0.56
PPARA Q07869 7/20 0.56
HDAC11 Q96DB2 5/20 0.56
TSHR P16473 5/20 0.56
PTPN1 P18031 3/20 0.56
ALDH1A1 P00352 3/20 0.56
TLR2 O60603 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
FABP4 P15090 2/20 0.56
SLC22A6 Q4U2R8 1/20 0.56
SLC22A8 Q8TCC7 1/20 0.56
MEN1 O00255 1/20 0.56
ESR1 P03372 1/20 0.56
ALOX15 P16050 1/20 0.56
PDE4A P27815 1/20 0.56
KMT2A Q03164 1/20 0.56
PDE3A Q14432 1/20 0.56
HSD17B10 Q99714 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22835020 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL4830079 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL17163937 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL25177394 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL22835017 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL25184994 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL25199003 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL25211905 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL20820026 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11
SCHEMBL1147991 1.00 GPR84 (0.56) GPR84PPARGPPARDPPARAHDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118459479-A Dumbbell-type fullerene condensed ring derivative and preparation method and application thereof 中国科学院化学研究所 2024-08-09 CN claimed
EP-3169403-B9 ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES PROTAGONIST THERAPEUTICS INC (US) 2024-07-03 EP claimed
EP-3169403-B1 ORAL PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY BOWEL DISEASES PROTAGONIST THERAPEUTICS INC (US) 2024-02-14 EP claimed
WO-2024030977-A2 NOVEL MELANOCORTIN ANALOGS SIGHTSTREAM BIOTHERAPEUTICS, INC. (US) 2024-02-08 WO claimed
CN-116840387-A Potential typing metabolic marker for nephrotic syndrome and metabolic marker related to lesion process and application of potential typing metabolic marker 山西大学 2023-10-03 CN claimed
CN-114507303-A External electron donor for olefin polymerization, catalyst system and olefin polymerization method 中国石油化工股份有限公司 2022-05-17 CN claimed
CN-114478870-A Catalyst system for olefin polymerization and olefin polymerization method 中国石油化工股份有限公司 2022-05-13 CN claimed
CN-107206254-B Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel disease 领导医疗有限公司 2021-08-24 CN claimed
US-10017481-B2 Conformationally constrained, fully synthetic macrocyclic compounds POLYPHOR AG (CH) 2018-07-10 US claimed
EP-2836485-B1 CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS POLYPHOR AG (CH) 2018-01-10 EP claimed
WO-2005066207-A1 GLUCAGON-LIKE PEPTIDE-1 ANALOGS WITH LONG DURATION OF ACTION THERATECHNOLOGIES INC. (CA) 2005-07-21 WO claimed
US-6864229-B2 G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) 2005-03-08 US claimed
US-20030148449-A1 G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same TUFTS MEDICAL CENTER, INC. 2003-08-07 US claimed
EP-1278777-A2 G PROTEIN COUPLED RECEPTOR (GPCR) AGONISTS AND ANTAGONISTS AND METHODS OF ACTIVATING AND INHIBITING GPCR USING THE SAME New England Medical Center (US) 2003-01-29 EP claimed
WO-2001081408-A9 G-PROTEIN COUPLED RECEPTOR (GPCR) AGONISTS AND ANTAGONISTS AND METHODS OF ACTIVATING AND INHIBITING GPCR USING THE SAME NEW ENGLAND MEDICAL CT (US) 2003-01-03 WO claimed
US-20020076755-A1 G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same TUFTS MEDICAL CENTER, INC. 2002-06-20 US claimed
JP-2002507591-A 2002-03-12 JP claimed
WO-2001081408-A2 G-PROTEIN COUPLED RECEPTOR (GPCR) AGONISTS AND ANTAGONISTS AND METHODS OF ACTIVATING AND INHIBITING GPCR USING THE SAME NEW ENGLAND MEDICAL CENTER (US) 2001-11-01 WO claimed
EP-1064254-A2 ALIPHATIC AMINO CARBOXYLIC AND AMINO PHOSPHONIC ACIDS, AMINO NITRILES AND AMINO TETRAZOLES AS CELLULAR RESCUE AGENTS University of Saskatchewan Technologies Inc. (CA) 2001-01-03 EP claimed
WO-1999048858-A2 ALIPHATIC AMINO CARBOXYLIC AND AMINO PHOSPHONIC ACIDS, AMINO NITRILES AND AMINO TETRAZOLES AS CELLULAR RESCUE AGENTS UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. (CA) 1999-09-30 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10017481-B2 Conformationally constrained, fully synthetic macrocyclic compounds CTSE, CTSB, CTSS GPR84 596/4885PPARG 1974/4885PPARD 3264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.